Attached files
file | filename |
---|---|
10-Q - 10-Q - Sarepta Therapeutics, Inc. | a10-12966_110q.htm |
EX-3.2 - EX-3.2 - Sarepta Therapeutics, Inc. | a10-12966_1ex3d2.htm |
EX-31.1 - EX-31.1 - Sarepta Therapeutics, Inc. | a10-12966_1ex31d1.htm |
EX-31.2 - EX-31.2 - Sarepta Therapeutics, Inc. | a10-12966_1ex31d2.htm |
EX-10.84 - EX-10.84 - Sarepta Therapeutics, Inc. | a10-12966_1ex10d84.htm |
EXHIBIT 32.1
CERTIFICATION OF CEO AND CFO PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Quarterly Report of AVI BioPharma, Inc. (the Company) on Form 10-Q for the period ended June 30, 2010 as filed with the Securities and Exchange Commission on the date hereof (the Report), I, J. David Boyle II, as Interim President and Chief Executive Officer and Senior Vice President and Chief Financial Officer of the Company, and I Melinda K. Miles, Controller and Chief Accounting Officer of the Company, hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to the best of my knowledge:
(1) The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
/s/ J. David Boyle II |
|
J. David Boyle II
Interim President and Chief Executive Officer, and Senior Vice President and Chief Financial Officer
AVI BioPharma, Inc.
August 9, 2010
/s/ Melinda K. Miles |
|
Melinda K. Miles
Controller and Chief Accounting Officer
AVI BioPharma, Inc.
August 9, 2010
This certification accompanies the Report pursuant to § 906 of the Sarbanes-Oxley Act of 2002 and shall not, except to the extent required by the Sarbanes-Oxley Act of 2002, be deemed filed by the Company for purposes of §18 of the Securities Exchange Act of 1934, as amended.
See also the certification pursuant to Sec. 302 of the Sarbanes-Oxley Act of 2002, which is also attached to this report.
A signed original of this written statement required by Section 906 of the Sarbanes-Oxley Act of 2002 has been provided to AVI BioPharma, Inc. and will be retained by AVI BioPharma, Inc. and furnished to the Securities and Exchange Commission or its staff upon request.